Inhibition of Phosphomonoesterase Activity of Protein Tyrosine Phosphatase-1B by 2-Hydroxyl-1,4-Naphthoquinone (2HNQ) in the Repression of Cancer Progression
1
Biochemistry, KWARA STATE UNIVERSITY, MALETE, Malete, Nigeria
2
Biochemistry, University of Ilorin, Ilorin, Nigeria
3
Medical Laboratory Science, KWARA STATE UNIVERSITY, MALETE, Malete, Nigeria
Popul. Med. 2026;8(Supplement Supplement 1):A2854
ABSTRACT
INTRODUCTION:
Protein tyrosine phosphatase is a non-receptor protein observed in enhancing many cellular signaling, due to its ubiquitous nature in all subcellular components. However, PTPIB has been reported to serve an oncogenic role by driving the activation of c-Src activity in promoting cell growth, mostly in breast cancer, colon cancer, and tumors. The discovery has resulted in the inhibitory regulation of PTP1B protein to mitigate the aberrant dephosphorylation of tyrosine in subcellular compartments that consist of this enzyme for cellular signalling. This study aims to investigate the potential of 2HNQ as an inhibitor of PTP1B, a critical regulator of immune response and cancer development.
METHODS:
The concentration-dependent inhibition of PTP1B by 2HNQ was carried out by varying the concentration of 2HNQ (62.5, 125, 250, 500, 750, 1000, and 1250 µM) while keeping the concentration of pNPP (substrate) constant at 25 mM, using the ELISA technique. The mode of inhibition of PTP1B was carried out using the concentration of 2HNQ with the highest percentage inhibition while varying the concentrations of pNPP (10, 20, 40, 80, 160, 200, 240, and 300 mM).
RESULTS:
The results obtained from this study revealed that 2HNQ inhibited PTP1B at concentrations of 125 µM, 750 µM, and 1250 µM. The double-reciprocal transformation plot indicated a non-competitive mode of inhibition in the presence of 125 µM, 750 µM, and 1250 µM 2HNQ.
CONCLUSIONS:
These findings suggest that 2HNQ may have therapeutic implications for cancer and autoimmune diseases through its inhibitory ability on PTP1B. Recommendation: Further research, including in vivo and clinical studies, is needed to fully explore its potential and mechanisms of action. This study offers a promising avenue for cancer immunotherapy and immune-related disease treatment.
Protein tyrosine phosphatase is a non-receptor protein observed in enhancing many cellular signaling, due to its ubiquitous nature in all subcellular components. However, PTPIB has been reported to serve an oncogenic role by driving the activation of c-Src activity in promoting cell growth, mostly in breast cancer, colon cancer, and tumors. The discovery has resulted in the inhibitory regulation of PTP1B protein to mitigate the aberrant dephosphorylation of tyrosine in subcellular compartments that consist of this enzyme for cellular signalling. This study aims to investigate the potential of 2HNQ as an inhibitor of PTP1B, a critical regulator of immune response and cancer development.
METHODS:
The concentration-dependent inhibition of PTP1B by 2HNQ was carried out by varying the concentration of 2HNQ (62.5, 125, 250, 500, 750, 1000, and 1250 µM) while keeping the concentration of pNPP (substrate) constant at 25 mM, using the ELISA technique. The mode of inhibition of PTP1B was carried out using the concentration of 2HNQ with the highest percentage inhibition while varying the concentrations of pNPP (10, 20, 40, 80, 160, 200, 240, and 300 mM).
RESULTS:
The results obtained from this study revealed that 2HNQ inhibited PTP1B at concentrations of 125 µM, 750 µM, and 1250 µM. The double-reciprocal transformation plot indicated a non-competitive mode of inhibition in the presence of 125 µM, 750 µM, and 1250 µM 2HNQ.
CONCLUSIONS:
These findings suggest that 2HNQ may have therapeutic implications for cancer and autoimmune diseases through its inhibitory ability on PTP1B. Recommendation: Further research, including in vivo and clinical studies, is needed to fully explore its potential and mechanisms of action. This study offers a promising avenue for cancer immunotherapy and immune-related disease treatment.
| eISSN: | 2654-1459 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
